Compounds Combining Aminoadamantane and Monoterpene Moieties: Cytotoxicity and Mutagenic Effects

• Published in: Medicinal chemistry (Shp-sariqah, United Arab Emirates) Vol. 11; no. 7; p. 629
• Main Authors: Suslov, Evgeniy V, Ponomarev, Konstantin Yu, Rogachev, Artem D, Pokrovsky, Michail A, Pokrovsky, Andrey G, Pykhtina, Maria B, Beklemishev, Anatoly B, Korchagina, Dina V, Volcho, Konstantin P, Salakhutdinov, Nariman F
• Format: Journal Article
• Language: English
• Published: Netherlands 01.01.2015
• Subjects: Adamantane - chemistry; Adamantane - pharmacology; Animals; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Cell Line, Tumor; Dogs; Humans; Madin Darby Canine Kidney Cells; Monoterpenes - chemistry; Mutagens - chemistry; Mutagens - pharmacology
• DOI: 10.2174/1573406411666150518110053

A series of secondary amines combining monoterpenoid and aminoadamantane moieties have been synthesized. Their cytotoxic activity against human cancer cells CEM-13, MT-4, and U-937 has been studied for the first time. Most of the obtained compounds exhibited a significant cytotoxic activity with the median cytotoxic dose (CTD50) ranging from 6 to 84 µM. The most promising results were obtained for compound 2b which was synthesized from 1-aminoadamantane and (-)-myrtenal and revealed a high activity against all tumor lines used (CTD50 = 12 ÷ 21 µM) along with low toxicity with respect to MDCK cells (CTD50 = 1500 µM). The synthesized amines do not exert the genotoxic effect on cells of the biosensor strain based on recombinant E. coli cells bearing the pRAC-gfp plasmid.